Clinical and translational study on chronic hepatitis Bincreasing contribution from China

来源 :2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议 | 被引量 : 0次 | 上传用户:liujia6949
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Over the last decades,two interferons(IFN) and five nucleos(t)ide analogues(NUC) have been approved for the treatment of chronic hepatitis B(CHB).However,choosing IFN or NUC sometimes is an issue of decision-making process.
其他文献
会议
会议
会议
会议
会议
Chronic hepatitis,cirrhosis,and hepatocellular carcinoma(HCC) are considered to be sequential adverse outcomes in patients with persistent hepatitis B virus(HBV
会议
会议
Hepatocellular carcinoma(HCC) is common and is closely related with chronic viral infections of the liver.In most Asian and African countries,70 %~80 %of HCC are
会议
Management of chronic hepatitis B is complicated because the natural course of chronic HBV infection is characterized by periods of activity interspersed with p
会议
会议